Ataxia Market Report 2026

Ataxia Market Overview

• Ataxia market size has reached to $40.45 billion in 2025 • Expected to grow to $61.91 billion in 2030 at a compound annual growth rate (CAGR) of 8.9% • Growth Driver: Alarming Surge In Alcohol Consumption Spurs Growth In The Ataxia Market • Market Trend: Revolutionizing Ataxia Treatment With Groundbreaking Drug Targeting • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Ataxia Market?

Ataxia is a neurological disorder that causes erratic movements and balance issues due to a loss of muscular control and coordination. It impacts the limbs, speech, and eye movements, among other body regions. The main types of ataxias are Friedreich's ataxia, ataxia-telangiectasia, episodic ataxia, and others. Friedreich's ataxia refers to a rare genetic condition that impairs movement and gradually damages the nervous system. It can be treated with various products, including treatment and diagnosis. The several types of dosage forms are included, such as solids, liquids, and others, which can be administered through various routes, including oral, parenteral, and others. It is used by several end-users, such as hospitals, clinics, home healthcare, and others.

What Is The Ataxia Market Growth Forecast?

The ataxia market size is expected to see strong growth in the next few years. It will grow to $61.91 billion in 2030 at a compound annual growth rate (CAGR) of 8.9%. The growth in the forecast period can be attributed to increasing investments in gene-based therapies, rising adoption of personalized neurology treatments, expansion of digital monitoring for neurological conditions, growing focus on rare disease drug development, increasing collaboration in neurological research. Major trends in the forecast period include increasing focus on genetic testing and counseling, rising adoption of symptomatic treatment approaches, growing use of advanced neurodiagnostic tools, expansion of long-term disease management strategies, enhanced emphasis on early diagnosis.

Global Ataxia Market Segmentation

1) By Disease Type: Friedreich's Ataxia, Ataxia-telangiectasia, Episodic Ataxia, Other Disease Types 2) By Product: Treatment, Diagnosis 3) By Dosage Form: Solid, Liquids, Other Dosage Forms 4) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration 5) By End User: Hospital, Clinics, Home Healthcare, Other End-Users Subsegments: 1) By Friedreich's Ataxia: Genetic Counseling And Testing, Symptomatic Treatments 2) By Ataxia-telangiectasia: Immunotherapy, Supportive Care 3) By Episodic Ataxia: Medications For Episodes, Long-term Management Strategies 4) By Other Disease Types: Spinocerebellar Ataxias (SCAs), Ataxia Due To Vitamin Deficiencies Or Toxins

What Is The Driver Of The Ataxia Market?

The rise in alcohol consumption is expected to propel the growth of the ataxia market going forward. Alcohol consumption refers to drinking an ethanol-containing beverage, usually orally. Cerebellar degeneration, a prevalent kind of acquired toxic ataxia, is caused by chronic alcohol misuse. Patients with alcoholism experience lower limb postural tremors and gait ataxia. For instance, in August 2024, according to GOV.UK, a UK-based government department, the provisional total for alcohol duty receipts from wine and other fermented products between May and July 2024 is $1,523 million (£1,154 million), reflecting an increase of $42 million (£32 million) (2.9%) compared to the same period last year. Therefore, the rise in alcohol consumption is driving the growth of the ataxia industry.

Key Players In The Global Ataxia Market

Major companies operating in the ataxia market are Pfizer Inc., Johnson & Johnson Services Inc., Eisai Co. Ltd., Genentech Inc., CRISPR Therapeutics AG, Eli Lilly & Company, GlaxoSmithKline Plc, Larimar Therapeutics Inc., Capsida Biotherapeutics Inc., Intellia Therapeutics Inc., Bluebird bio Inc., Editas Medicine Inc., Healx, Acorda Therapeutics Inc., H. Lundbeck A/S, Reata Pharmaceuticals Inc., PTC Therapeutics, Ionis Pharmaceuticals Inc., IntraBio, Biogen Inc., Novartis AG, Sanofi, Roche Holding Ltd., Teva Pharmaceuticals, Zydus Lifesciences Ltd

Global Ataxia Market Trends and Insights

Major companies operating in the ataxia market are focusing on developing innovative solutions, such as first-in-class oral drug therapies, to meet the rising demand for effective treatment options that can slow disease progression and improve functional outcomes in rare neurodegenerative disorders. These oral therapies offer a convenient, non-invasive alternative to traditional supportive care approaches that primarily manage symptoms without modifying underlying disease pathways. For instance, in February 2023, Reata Pharmaceuticals, a US-based biotechnology company, announced the FDA's (the U.S. Food and Drug Administration's) approval of SKYCLARYS (omavaloxolone). It is the first and only drug indicated for patients with Friedreich's ataxia in adults and adolescents aged 16. At Week 48, treatment with the oral, once-daily medication SKYCLARYS led to statistically significant lower mFARS (modified Friedreich's Ataxia Rating Scale) scores (reduced impairment) compared to placebo. The diagnosis of Friedreich's ataxia, an extremely rare inherited neurological condition, usually occurs around adolescence.

What Are Latest Mergers And Acquisitions In The Ataxia Market?

In September 2023, Biogen, a US-based biopharmaceutical company, acquired Reata Pharmaceuticals for $7.3 billion. Through this acquisition, Biogen aims to expand its presence in the ataxia market by integrating Reata’s lead therapy, SKYCLARYS® (omaveloxolone), and leveraging its pipeline of therapeutics targeting neurodegenerative and mitochondrial disorders. Reata Pharmaceuticals is a US-based biopharmaceutical company that provides novel small-molecule therapeutics, including the first FDA-approved treatment for Friedreich’s ataxia.

Regional Outlook

North America was the largest region in the ataxia market in 2025. Asia-Pacific is expected to be the fastest-growing region in the ataxia market report during the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Ataxia Market?

The ataxia market consists of revenues earned by entities by providing serotonergic therapy, occupational therapy, vestibular rehabilitation, and hyperbaric oxygen therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The ataxia market also includes sales of adaptive devices including walkers or canes, acetazolamide, and amantadine. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Ataxia Market Report 2026?

The ataxia market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the ataxia industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.